AMP hydrolysis reduction in blood plasma of breast cancer elderly patients after different treatments

Gheler, Fernanda Valente; Cappellari, Angélica Regina; Renck, Daiana; Souza, Julia Brandt de; Melo, Renan Oliveira de; Moriguchi, Carolina Aiko; Engroff, Paula; Lambert, Ana Paula Franco; Rockenbach, Liliana; Morrone, Fernanda Bueno

doi:10.1007/s11010-021-04199-x

Cited by 3 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD73 is investigated as a potential biomarker indicating the magnitude of treatment response in various cancer types. In a prospective cohort study it was shown that AMP hydrolysis in the blood plasma of elderly breast cancer patients was higher than in healthy elderly women and significantly decreased after every mode of therapy [89]. The measurement of CD73 and adenosine signalling could be useful to select patients for therapies that modulate the purinergic pathway.…”

Section: Prognostic Value Of Cd73mentioning

confidence: 99%

The Clinical Significance of CD73 in Cancer

Bach

Winzer

Fiedler

et al. 2023

IJMS

View full text Add to dashboard Cite

The search for new and effective treatment targets for cancer immunotherapy is an ongoing challenge. Alongside the more established inhibitory immune checkpoints, a novel potential target is CD73. As one of the key enzymes in the purinergic signalling pathway CD73 is responsible for the generation of immune suppressive adenosine. The expression of CD73 is higher in tumours than in the corresponding healthy tissues and associated with a poor prognosis. CD73, mainly by the production of adenosine, is critical in the suppression of an adequate anti-tumour immune response, but also in promoting cancer cell proliferation, tumour growth, angiogenesis, and metastasis. The upregulation of CD73 and generation of adenosine by tumour or tumour-associated immune cells is a common resistance mechanism to many cancer treatments such as chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Therefore, the inhibition of CD73 represents a new and promising approach to increase therapy efficacy. Several CD73 inhibitors have already been developed and successfully demonstrated anti-cancer activity in preclinical studies. Currently, clinical studies evaluate CD73 inhibitors in different therapy combinations and tumour entities. The initial results suggest that inhibiting CD73 could be an effective option to augment anti-cancer immunotherapeutic strategies. This review provides an overview of the rationale behind the CD73 inhibition in different treatment combinations and the role of CD73 as a prognostic marker.

show abstract

Section: Prognostic Value Of Cd73mentioning

confidence: 99%

The Clinical Significance of CD73 in Cancer

Bach

Winzer

Fiedler

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Previous studies have demonstrated significant differences in nucleotide hydrolysis profiles between patients with prostate cancer, patients with breast cancer, and healthy controls [19,20]. The CD39/CD73-pathway-mediated production of ADO is widely acknowledged as the primary regulatory mechanism employed by regulatory T cells (Tregs).…”

Section: Introductionmentioning

confidence: 99%

Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer

Gardani,

Pedrazza,

Paz

et al. 2023

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

Prostate cancer (PC) is the most diagnosed tumor in males and ranks as the second leading cause of male mortality in the western world. The CD39 and CD73 enzymes play a crucial role in cancer regulation by degrading nucleotides and forming nucleosides. This study aimed to investigate the expression of the CD39 and CD73 enzymes as potential therapeutic targets for PC. The initial part of this study retrospectively analyzed tissue samples from 23 PC patients. Using the TissueFAXSTM cytometry platform, we found significantly higher levels of CD39—labeling its intensity compared to CD73. Additionally, we observed a correlation between the Gleason score and the intensity of CD39 expression. In the prospective arm, blood samples were collected from 25 patients at the time of diagnosis and after six months of treatment to determine the expression of CD39 and CD73 in the serum extracellular vesicles (EVs) and to analyze nucleotide hydrolysis. Notably, the expression of CD39 in the EVs was significantly increased compared to the CD73 and/or combined CD39/CD73 expression levels at initial collection. Furthermore, our results demonstrated positive correlations between ADP hydrolysis and the transurethral resection and Gleason score. Understanding the role of ectonucleotidases is crucial for identifying new biomarkers in PC.

show abstract